The company will be working on behalf of Martin Dow and Atco Laboratories, though it has not disclosed which products it will be manufacturing for them
In Pakistan’s pharmaceutical industry, the more sophisticated end of the industry — biologics, biosimilars, monoclonal antibodies and other injectable therapies produced through biotechnology — has mostly been the preserve of imports, licences and multinational partnerships.
Searle appears to be betting that this is about to change.
The Searle Company Ltd has informed the Pakistan Stock Exchange that its indirect subsidiary, Nextar Pharma (Pvt) Ltd, has entered into separate arrangements with Martin Dow Marker Ltd and Atco Laboratories Ltd for the potential manufacture of biological products at Nextar’s production facility. The announcement, made in the formal language of stock-exchange disclosure, was short. It did not name the products. It did not disclose financial terms. It did not specify volumes, timelines, margins, technology-transfer arrangements, or whether Nextar will be manufacturing active pharmaceutical ingredients, finished dosage forms, or undertaking some narrower form of sterile filling, packaging or release testing. But the strategic direction was unmistakable.
Reference Link:- https://profit.pakistantoday.com.pk/2026/06/15/searle-pakistan-subsidiary-to-begin-contract-manufacturing-of-biologics